Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6010 + Enlonstobart ± platinum chemotherapy in advanced NSCLC and solid tumors
ChiCTR2400089402Phase 2Not yet recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Sep 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of CPO301 in non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms (3 arms), sponsored by Shanghai East Hospital. Primary endpoints: Safety and tolerability, Maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) and 1 more. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
CPO301
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2400089402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089402.